SA519410320B1 - مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل - Google Patents
مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيلInfo
- Publication number
- SA519410320B1 SA519410320B1 SA519410320A SA519410320A SA519410320B1 SA 519410320 B1 SA519410320 B1 SA 519410320B1 SA 519410320 A SA519410320 A SA 519410320A SA 519410320 A SA519410320 A SA 519410320A SA 519410320 B1 SA519410320 B1 SA 519410320B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- phenyl
- compounds
- acetylamino
- hydroxy
- methyl
- Prior art date
Links
- -1 Phenyl-2-Hydroxy-Acetylamino-2-Methyl-Phenyl Compounds Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
يتعلق الاختراع الحالي بتوفير مركبات فينيل -2-هيدروكسي-أسيتيل أمينو-2-ميثيل-فينيل، وبتركيبات صيدلانية تشتمل على هذه المركبات، وبطرق لاستخدام المركبات لعلاج الاضطرابات الفسيولوجية مثل السرطان.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382207 | 2017-04-18 | ||
| PCT/US2018/027005 WO2018194885A1 (en) | 2017-04-18 | 2018-04-11 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA519410320B1 true SA519410320B1 (ar) | 2022-05-08 |
Family
ID=58606227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA519410320A SA519410320B1 (ar) | 2017-04-18 | 2019-10-17 | مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11655214B2 (ar) |
| EP (2) | EP3612519B1 (ar) |
| JP (2) | JP7110232B2 (ar) |
| KR (2) | KR20230129627A (ar) |
| CN (2) | CN117510405A (ar) |
| AU (2) | AU2018255191B2 (ar) |
| BR (1) | BR112019021867A2 (ar) |
| CA (1) | CA3060564A1 (ar) |
| CO (1) | CO2019012767A2 (ar) |
| CR (1) | CR20190519A (ar) |
| CY (1) | CY1125150T1 (ar) |
| DK (1) | DK3612519T3 (ar) |
| ES (1) | ES2906847T3 (ar) |
| HR (1) | HRP20220263T1 (ar) |
| HU (1) | HUE057745T2 (ar) |
| IL (2) | IL270005B (ar) |
| LT (1) | LT3612519T (ar) |
| MX (2) | MX2019012428A (ar) |
| PH (1) | PH12019502363A1 (ar) |
| PL (1) | PL3612519T3 (ar) |
| PT (1) | PT3612519T (ar) |
| RS (1) | RS62933B1 (ar) |
| SA (1) | SA519410320B1 (ar) |
| SG (1) | SG11201909680UA (ar) |
| SI (1) | SI3612519T1 (ar) |
| WO (1) | WO2018194885A1 (ar) |
| ZA (1) | ZA201906811B (ar) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230129627A (ko) | 2017-04-18 | 2023-09-08 | 일라이 릴리 앤드 캄파니 | 페닐-2-히드록시-아세틸아미노-2-메틸-페닐 화합물 |
| BR112020019023A2 (pt) | 2018-03-26 | 2020-12-29 | Icahn School Of Medicine At Mount Sinai | Métodos de tratamento do câncer residual mínimo |
| WO2021041973A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting compounds |
| US20220348584A1 (en) | 2019-08-29 | 2022-11-03 | Hibercell, Inc. | Perk inhibiting indolinyl compounds |
| JP2022546414A (ja) | 2019-08-29 | 2022-11-04 | ヒベルセル， インコーポレイテッド | Ｐｅｒｋ阻害ピロロピリミジン化合物 |
| WO2021041970A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting imidazolopyrazine compounds |
| WO2021231788A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds to treat viral infections |
| WO2021231782A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibitors for treating viral infections |
| CN113234029B (zh) * | 2021-05-25 | 2022-03-22 | 白银康寓信生物科技有限公司 | 一种2-氨基-3,5-二卤代吡嗪的合成方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID24653A (id) | 1997-03-19 | 2000-07-27 | Basf Ag | Zat-zat terapi |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| EP1501514B1 (en) | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| NZ580384A (en) * | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| KR20080040027A (ko) * | 2005-09-02 | 2008-05-07 | 아스테라스 세이야쿠 가부시키가이샤 | Ｒｏｃｋ 억제제로서 아미드 유도체 |
| ES2545760T3 (es) | 2008-02-25 | 2015-09-15 | Nestec S.A. | Selección de fármacos para terapia del cáncer de mama utilizando matrices de anticuerpos |
| US20120014911A1 (en) | 2009-01-09 | 2012-01-19 | Serge Fuchs | Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor |
| BR112012024380A2 (pt) | 2010-03-25 | 2015-09-15 | Glaxosmithkline Llc | compostos químicos |
| EP2986286A1 (en) | 2013-04-15 | 2016-02-24 | Universita' Degli Studi di Bari | Galloyl benzamide-based compounds as jnk modulators |
| WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
| WO2015068767A1 (ja) | 2013-11-08 | 2015-05-14 | 小野薬品工業株式会社 | ピロロピリミジン誘導体 |
| EP3116877A1 (en) | 2014-03-11 | 2017-01-18 | Glaxosmithkline Intellectual Property (No. 2) Limited | Chemical compounds acting as perk inhibitors |
| WO2016004254A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| CN107108631B (zh) | 2014-11-14 | 2020-06-16 | 内尔维阿诺医学科学有限公司 | 作为蛋白激酶抑制剂的6-氨基-7-二环-7-脱氮-嘌呤衍生物 |
| GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| BR112018001190A2 (pt) * | 2015-07-24 | 2018-09-11 | Blueprint Medicines Corp | composições úteis para tratar distúrbios relacionados a kit e pdfgr |
| WO2018009017A1 (en) | 2016-07-07 | 2018-01-11 | Daewoong Pharmaceutical Co., Ltd. | NOVEL 4-AMINOPYRAZOLO[3,4-d]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
| CN109789135A (zh) | 2016-07-20 | 2019-05-21 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为perk抑制剂的异喹啉衍生物 |
| CN106748989B (zh) | 2016-11-14 | 2020-03-17 | 西安交通大学 | 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用 |
| WO2018138358A1 (en) | 2017-01-30 | 2018-08-02 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
| KR20230129627A (ko) | 2017-04-18 | 2023-09-08 | 일라이 릴리 앤드 캄파니 | 페닐-2-히드록시-아세틸아미노-2-메틸-페닐 화합물 |
| WO2019099564A1 (en) | 2017-11-14 | 2019-05-23 | Children's Medical Center Corporation | Novel imidazopyrimidine compounds and uses thereof |
| EP3492454A1 (en) | 2017-11-30 | 2019-06-05 | Step Pharma S.A.S. | Compounds |
| BR112020019023A2 (pt) | 2018-03-26 | 2020-12-29 | Icahn School Of Medicine At Mount Sinai | Métodos de tratamento do câncer residual mínimo |
| US11186579B2 (en) | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| EP3860578A1 (en) | 2018-10-01 | 2021-08-11 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of inhibitors of stress granule formation for targeting the regulation of immune responses |
-
2018
- 2018-04-11 KR KR1020237029674A patent/KR20230129627A/ko not_active Application Discontinuation
- 2018-04-11 CN CN202310753648.5A patent/CN117510405A/zh active Pending
- 2018-04-11 JP JP2019556703A patent/JP7110232B2/ja active Active
- 2018-04-11 RS RS20220154A patent/RS62933B1/sr unknown
- 2018-04-11 PT PT187185707T patent/PT3612519T/pt unknown
- 2018-04-11 DK DK18718570.7T patent/DK3612519T3/da active
- 2018-04-11 HU HUE18718570A patent/HUE057745T2/hu unknown
- 2018-04-11 CR CR20190519A patent/CR20190519A/es unknown
- 2018-04-11 CA CA3060564A patent/CA3060564A1/en active Pending
- 2018-04-11 PL PL18718570T patent/PL3612519T3/pl unknown
- 2018-04-11 KR KR1020197033523A patent/KR102575246B1/ko active IP Right Grant
- 2018-04-11 EP EP18718570.7A patent/EP3612519B1/en active Active
- 2018-04-11 WO PCT/US2018/027005 patent/WO2018194885A1/en unknown
- 2018-04-11 SI SI201830572T patent/SI3612519T1/sl unknown
- 2018-04-11 SG SG11201909680U patent/SG11201909680UA/en unknown
- 2018-04-11 BR BR112019021867-0A patent/BR112019021867A2/pt unknown
- 2018-04-11 LT LTEPPCT/US2018/027005T patent/LT3612519T/lt unknown
- 2018-04-11 MX MX2019012428A patent/MX2019012428A/es unknown
- 2018-04-11 EP EP21211015.9A patent/EP4039675A1/en active Pending
- 2018-04-11 US US16/606,410 patent/US11655214B2/en active Active
- 2018-04-11 AU AU2018255191A patent/AU2018255191B2/en active Active
- 2018-04-11 ES ES18718570T patent/ES2906847T3/es active Active
- 2018-04-11 HR HRP20220263TT patent/HRP20220263T1/hr unknown
- 2018-04-11 CN CN201880033126.5A patent/CN110831927B/zh active Active
-
2019
- 2019-10-16 ZA ZA2019/06811A patent/ZA201906811B/en unknown
- 2019-10-17 IL IL270005A patent/IL270005B/en unknown
- 2019-10-17 PH PH12019502363A patent/PH12019502363A1/en unknown
- 2019-10-17 SA SA519410320A patent/SA519410320B1/ar unknown
- 2019-10-17 MX MX2022001310A patent/MX2022001310A/es unknown
- 2019-11-15 CO CONC2019/0012767A patent/CO2019012767A2/es unknown
-
2021
- 2021-12-09 IL IL288822A patent/IL288822B2/en unknown
-
2022
- 2022-03-01 CY CY20221100173T patent/CY1125150T1/el unknown
- 2022-07-18 AU AU2022206702A patent/AU2022206702B2/en active Active
- 2022-07-20 JP JP2022115300A patent/JP7331212B2/ja active Active
-
2023
- 2023-04-13 US US18/300,237 patent/US20230373922A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| WO2018140831A3 (en) | Tumor targeting conjugates and methods of use thereof | |
| MX2018014154A (es) | Polinucleotidos moduladores. | |
| PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| PH12016501898B1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| EA033163B1 (ru) | Ингибиторы глутаминазы | |
| MX2015012056A (es) | Inhibidores de indolamina-2,3-dioxigenasa (ido). | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| NZ761519A (en) | Nlrp3 modulators | |
| PH12017500853A1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| MX2017009608A (es) | Compuestos anticancerigenos. | |
| IN2013MU03118A (ar) | ||
| PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs | |
| JO3621B1 (ar) | مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll | |
| GB2553684A8 (en) | Ethynylxanthines, preparation and use for cancer treatment |